These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35124132)

  • 41. Long-Term Clinical Outcomes of Pencil Beam Scanning Proton Therapy for Benign and Non-benign Intracranial Meningiomas.
    Murray FR; Snider JW; Bolsi A; Lomax AJ; Walser M; Kliebsch U; Schneider RA; Weber DC
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1190-1198. PubMed ID: 28939227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility and robustness of dose painting by numbers in proton therapy with contour-driven plan optimization.
    Barragán AM; Differding S; Janssens G; Lee JA; Sterpin E
    Med Phys; 2015 Apr; 42(4):2006-17. PubMed ID: 25832091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proton Beam Therapy for Locally Advanced Head and Neck Tumors: An Analysis of Dosimetric and Clinical Outcomes.
    Sheikh S; Kharouta MZ; Pidikiti R; Damico NJ; Choi S; Dorth JA; Mansur DB; Machtay MX; Yao M; Bhatt AD
    Am J Clin Oncol; 2022 Feb; 45(2):81-87. PubMed ID: 35073281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relation between prediction model performance measures and patient selection outcomes for proton therapy in head and neck cancer.
    Leeuwenberg AM; Reitsma JB; Van den Bosch LGLJ; Hoogland J; van der Schaaf A; Hoebers FJP; Wijers OB; Langendijk JA; Moons KGM; Schuit E
    Radiother Oncol; 2023 Feb; 179():109449. PubMed ID: 36566991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis.
    Jakobi A; Bandurska-Luque A; Stützer K; Haase R; Löck S; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1165-1174. PubMed ID: 26194685
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and Validation of a Normal Tissue Complication Probability Model for Lymphedema After Radiation Therapy in Breast Cancer.
    Park YI; Chang JS; Ko H; Im SH; Kim JS; Byun HK; Kim YB; Jung W; Kim K; Hong CS
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1218-1225. PubMed ID: 36739918
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Automated Robust Proton Planning Using Dose-Volume Histogram-Based Mimicking of the Photon Reference Dose and Reducing Organ at Risk Dose Optimization.
    Kierkels RGJ; Fredriksson A; Both S; Langendijk JA; Scandurra D; Korevaar EW
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):251-258. PubMed ID: 30145392
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy.
    Hansen CR; Friborg J; Jensen K; Samsøe E; Johnsen L; Zukauskaite R; Grau C; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Eriksen JG; Overgaard J
    Acta Oncol; 2019 Oct; 58(10):1410-1415. PubMed ID: 31432744
    [No Abstract]   [Full Text] [Related]  

  • 49. Radiobiological and dosimetric impact of RayStation pencil beam and Monte Carlo algorithms on intensity-modulated proton therapy breast cancer plans.
    Rana S; Greco K; Samuel EJJ; Bennouna J
    J Appl Clin Med Phys; 2019 Aug; 20(8):36-46. PubMed ID: 31343826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predicting High-Grade Esophagus Toxicity After Treating Central Lung Tumors With Stereotactic Radiation Therapy Using a Normal Tissue Complication Probability Model.
    Duijm M; van der Voort van Zyp NC; van de Vaart P; Oomen-de Hoop E; Mast ME; Hoogeman MS; Nuyttens JJ
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):73-81. PubMed ID: 31499137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapy.
    Pedersen J; Flampouri S; Bryant C; Liang X; Mendenhall N; Li Z; Liu M; Muren LP
    Radiother Oncol; 2020 Jan; 142():253-260. PubMed ID: 31630864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of Robustness to Setup and Range Uncertainties for Head and Neck Patients Treated With Pencil Beam Scanning Proton Therapy.
    Malyapa R; Lowe M; Bolsi A; Lomax AJ; Weber DC; Albertini F
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):154-162. PubMed ID: 27084638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estimating the Dose-Response Relationship for Ocular Pain after Radiotherapy of Head and Neck Cancers and Skull Base Tumors based on the LKB Radiobiological Model.
    Momeni N; Broomand MA; Roozmand Z; Hamzian N
    J Biomed Phys Eng; 2023 Oct; 13(5):411-420. PubMed ID: 37868939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
    Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Normal tissue complication probability modeling to guide individual treatment planning in pediatric cranial proton and photon radiotherapy.
    Dell'Oro M; Wilson P; Short M; Hua CH; Merchant TE; Bezak E
    Med Phys; 2022 Jan; 49(1):742-755. PubMed ID: 34796509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Empirical Relative Biological Effectiveness (RBE) for Mandible Osteoradionecrosis (ORN) in Head and Neck Cancer Patients Treated With Pencil-Beam-Scanning Proton Therapy (PBSPT): A Retrospective, Case-Matched Cohort Study.
    Yang Y; Muller OM; Shiraishi S; Harper M; Amundson AC; Wong WW; McGee LA; Rwigema JM; Schild SE; Bues M; Fatyga M; Anderson JD; Patel SH; Foote RL; Liu W
    Front Oncol; 2022; 12():843175. PubMed ID: 35311159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term outcomes and prognostic factors of skull-base chondrosarcoma patients treated with pencil-beam scanning proton therapy at the Paul Scherrer Institute.
    Weber DC; Badiyan S; Malyapa R; Albertini F; Bolsi A; Lomax AJ; Schneider R
    Neuro Oncol; 2016 Feb; 18(2):236-43. PubMed ID: 26323608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
    Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
    J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head.
    Raturi VP; Hojo H; Hotta K; Baba H; Takahashi R; Rachi T; Nakamura N; Zenda S; Motegi A; Tachibana H; Ariji T; Motegi K; Nakamura M; Okumura M; Hirano Y; Akimoto T
    Radiat Oncol; 2020 Jun; 15(1):157. PubMed ID: 32571379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.
    Chapet O; Kong FM; Lee JS; Hayman JA; Ten Haken RK
    Radiother Oncol; 2005 Nov; 77(2):176-81. PubMed ID: 16256230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.